Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $253.9552W HIGH $385.22
Volume
361.61 K
Value Traded
298.03 M
Short % Float
1.86%
+0.39%Week
+1.44%1 Month
+10.73%3 Month
+9.6%6 Month
-9.94%5 Year
+970.94%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
38.59 B
EPS (TTM)
5.80
P/E Ratio
60.64
Ent. Value
34.47 B
Total Shares
109.72 M
Float Shares
103.72 M
Insiders
0.53%
Institutions
33.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ONC Catalyst Timeline
Dated clinical, regulatory and corporate events for BeOne Medicines Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BeOne Medicines Ltd.
845Total events
26Upcoming
405Tier-1 (high impact)
2018 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Interim AnalysisZIIHERAApprovedTrial
Positive interim analysis 2 results from HERIZON-GEA-01
HER2-positive gastroesophageal adenocarcinoma (GEA)source ↗
▲Interim AnalysisZIIHERAApprovedTrial
Positive preliminary results from second interim analysis (IA2) of HERIZON-GEA-01
HER2-positive gastroesophageal adenocarcinoma (GEA)source ↗
▲Topline ReadoutZIIHERAApprovedClinical Data
ZIIHERA plus chemotherapy met OS endpoint at IA2
HER2+ gastroesophageal adenocarcinomasource ↗
▲Primary Endpoint MetZIIHERAApprovedClinical Data
ZIIHERA plus chemo met remaining primary endpoint OS at IA2
HER2+ gastroesophageal adenocarcinomasource ↗
▲Partnership / LicenseCorporate
Voluntary agreement with U.S. Government to expand access to cancer medicines
▲Manufacturing MilestoneCMC / Inspection
$300 million onshoring investment in Hopewell, NJ facility
▲Supplemental ApprovalTEVIMBRAApprovedFDA Decision
FDA approval of TEVIMBRA-based therapy for first-line HER2-positive GEA
HER2-positive GEAsource ↗
▲Priority ReviewTEVIMBRAApprovedRegulatory Filing
FDA granted Priority Review to sBLA for TEVIMBRA in combination with ZIIHERA and chemotherapy
first-line treatment of unresectable locally advanced/metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinomasource ↗
▲Breakthrough Therapy DesignationZIIHERAApprovedDesignation
FDA granted Breakthrough Therapy Designation to ZIIHERA in combination with chemotherapy, with and without TEVIMBRA
first-line treatment of unresectable locally advanced/metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinomasource ↗
▲Topline ReadoutTEVIMBRAApprovedClinical Data
First interim analysis (IA1) results of HERIZON-GEA-01 reported
advanced/metastatic HER2+ GEAsource ↗
▲Primary Endpoint MetTEVIMBRAApprovedClinical Data
HERIZON-GEA-01 met dual primary endpoints of OS and PFS
advanced/metastatic HER2+ GEAsource ↗
●sBLA SubmissionTEVIMBRAApprovedRegulatory Filing
sBLA submitted for TEVIMBRA plus ZIIHERA and chemotherapy
first-line treatment of unresectable locally advanced/metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinomasource ↗
▲Primary Endpoint MetZIIHERAApprovedClinical Data
HERIZON-GEA-01 IA1: ZIIHERA plus chemotherapy met primary endpoint of PFS
advanced/metastatic HER2+ GEAsource ↗
▲FDA Filing AcceptedTEVIMBRAApprovedRegulatory Filing
sBLA submission for TEVIMBRA plus ZIIHERA and chemotherapy accepted with Priority Review
first-line treatment of unresectable locally advanced/metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinomasource ↗
▲Supplemental ApprovalZIIHERAApprovedFDA Decision
FDA approved sBLA for ZIIHERA in combination with chemotherapy for first-line HER2+ GEA
HER2+ gastric, gastroesophageal junction, or esophageal adenocarcinomasource ↗
▲Supplemental ApprovalTEVIMBRAApprovedFDA Decision
Supplemental BLA approval for TEVIMBRA-based regimen in HER2+ GEA
first-line HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA)source ↗
▲FDA ApprovalZIIHERAApprovedFDA Decision
FDA approved ZIIHERA sBLA for first-line HER2+ GEA
HER2+ gastric, gastroesophageal junction, or esophageal adenocarcinomasource ↗
▲FDA ApprovalTEVIMBRAApprovedFDA Decision
FDA approves TEVIMBRA plus ZIIHERA and chemotherapy for first-line HER2+ GEA
first-line HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA)source ↗
▲Partnership / LicenseBRUKINSA®ApprovedCorporate
Partnership renewed to expand access to BRUKINSA in low- and middle-income countries
chronic lymphocytic leukemia (CLL)source ↗
▲Topline ReadoutBRUKINSA®ApprovedClinical Data
MANGROVE topline results: BRUKINSA plus rituximab met primary endpoint of PFS
mantle cell lymphomasource ↗
▲Primary Endpoint MetBRUKINSA®ApprovedClinical Data
MANGROVE met primary endpoint of PFS
mantle cell lymphomasource ↗
▲Partnership / LicenseCorporate
BeOne and Revolution Medicines announce clinical collaboration and regional commercialization agreement
RAS-addicted cancerssource ↗
●Quarterly UpdateCorporate
BeOne Medicines reports Q2 2026 financial results and corporate updates
▲Primary Endpoint MetBRUKINSA®ApprovedClinical Data
Positive topline results from Phase 3 MANGROVE study showing PFS superiority
mantle cell lymphomasource ↗
▲Full ResultsBRUKINSA®ApprovedClinical Data
Long-term 78-month follow-up data from Phase 3 SEQUOIA study presented at ASCO and EHA
chronic lymphocytic leukemiasource ↗
▲FDA ApprovalBEQALZIApprovedFDA Decision
FDA accelerated approval for R/R MCL after at least two lines of systemic therapy
relapsed or refractory mantle cell lymphomasource ↗
▲Other Regulator MilestoneTEVIMBRAApprovedEx-US Regulatory
Japan regulatory approval for first-line gastric cancer
gastric cancersource ↗
▲Full ResultsZIIHERAApprovedClinical Data
NEJM publication of full results from Phase 3 HERIZON-GEA-01 study
HER2-positive gastroesophageal adenocarcinomasource ↗
●Oral PresentationPresentation
Investor event at ASCO highlighting proof-of-concept data for three solid tumor programs
solid tumorssource ↗
▲Enrollment CompleteTacabrutidegTrial
Last patient enrolled in Phase 3 CaDAnCe-303 study
relapsed or refractory chronic lymphocytic leukemiasource ↗
▲First Patient DosedBG-75202Trial
First patient enrolled into monotherapy cohort for Phase 1 study
acute myeloid leukemiasource ↗
▲Trial InitiationBGB-43395Trial
Initiated Phase 3 study in combination with letrozole for first-line treatment
HR-positive, HER2-negative metastatic breast cancersource ↗
▲Orphan Drug DesignationBGB-58067Designation
FDA Orphan Drug Designation for pancreatic ductal adenocarcinoma
pancreatic ductal adenocarcinomasource ↗
▲Topline ReadoutBRUKINSA®ApprovedClinical Data
Positive topline results from Phase 3 MANGROVE study in MCL
mantle cell lymphomasource ↗
▲Full ResultsBRUKINSA®ApprovedClinical Data
78-month follow-up data from SEQUOIA presented at ASCO/EHA
chronic lymphocytic leukemiasource ↗
▲FDA ApprovalBEQALZIApprovedFDA Decision
FDA accelerated approval for BEQALZI in R/R MCL
relapsed or refractory mantle cell lymphomasource ↗
▲Other Regulator MilestoneTEVIMBRAApprovedEx-US Regulatory
Japan approval for TEVIMBRA in first-line gastric cancer
gastric cancersource ↗
▲PublicationZIIHERAApprovedPresentation
NEJM publication of HERIZON-GEA-01 full results
HER2+ gastroesophageal adenocarcinomasource ↗
▲Oral PresentationBGB-43395Presentation
Investor event at ASCO highlighting proof-of-concept data for BGB-43395
solid tumorssource ↗
▲Oral PresentationBGB-B2033Presentation
Investor event at ASCO highlighting proof-of-concept data for BGB-B2033
solid tumorssource ↗
▲Oral PresentationBG-C9074Presentation
Investor event at ASCO highlighting proof-of-concept data for BG-C9074
solid tumorssource ↗
▲Manufacturing MilestoneCMC / Inspection
$300 million expansion of Hopewell manufacturing facility announced
▲Primary Endpoint MetBRUKINSA®ApprovedClinical Data
Risultati positivi di fase 3 per BRUKINSA nel MCL di prima linea
linfoma a cellule mantellari (MCL) di prima lineasource ↗
◆Other Regulator MilestoneTEVIMBRAApprovedEx-US Regulatory
Japan regulatory action for TEVIMBRA in first-line gastric cancer
first-line gastric cancersource ↗
●Trial InitiationSonrotoclaxApprovedTrial
Phase 3 trial initiation for Sonrotoclax in R/R multiple myeloma t(11;14)
R/R multiple myeloma t(11;14)source ↗
●Timing GuidanceTacabrutidegPresentation
Potential accelerated approval submission for BGB-16673 in R/R CLL (if data support)
R/R CLLsource ↗
●Trial InitiationBGB-B2033Trial
Potentially registrational Phase 2 trial initiation for BGB-B2033 (GPC3x41BB bispecific)
gastrointestinal cancerssource ↗
◆Topline ReadoutBGB-45035Clinical Data
Phase 1/2 trial data readout for BGB-45035 (IRAK4 CDAC) in rheumatoid arthritis
rheumatoid arthritissource ↗
Past FDA Catalysts and PDUFA Decisions
How ONC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-25 | Tevimbra (tislelizumab-jsgr) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
35
Drugs Scored
rNPV / MCap
Top Drug
Top 4%
Mid Cap(rank 27 of 656)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| BRUKINSA | |||
| TEVIMBRA | |||
| XGEVA | |||
| BLINCYTO | |||
| KYPROLIS | |||
| POBEVCY |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BGB-43395 Small moleculeNCT07492641 | HR+/HER2- Breast Cancer | Phase 3 | RECRUITING | 1,056 | Aug 7, 2037 | ||||||
| BGB-A445 Small moleculeNCT05661955 | Urothelial Carcinoma | Phase 1 | ACTIVE NOT_RECRUITING | 113 | Oct 1, 2026 | ||||||
| Tislelizumab Monoclonal antibodyMarketedNCT06091943 | Non Small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 2,575 | Jul 31, 2026 | ||||||
| Tislelizumab Monoclonal antibodyMarketedNCT07715396 | Non-small Cell Lung Cancer Metastatic | Phase 3 | NOT YET_RECRUITING | 230 | Oct 30, 2031 | ||||||
| Tislelizumab Monoclonal antibodyNCT03967977 | Urothelial Carcinoma | Phase 3 | ACTIVE NOT_RECRUITING | 420 | Oct 21, 2027 | ||||||
| Tislelizumab Monoclonal antibodyMarketedNCT07043400 | Metastatic Gastric Adenocarcinoma | Phase 3 | RECRUITING | 351 | Apr 22, 2028 | ||||||
| Tislelizumab Monoclonal antibodyNCT05909904 | Head and Neck Squamous Cell Carcinoma | Phase 2 | ACTIVE NOT_RECRUITING | 160 | May 28, 2026 | ||||||
| Tislelizumab Monoclonal antibodyNCT03736889 | MSI-H/dMMR Solid Tumors | Phase 2 | RECRUITING | 200 | Sep 1, 2027 | ||||||
| Tislelizumab Monoclonal antibodyMarketedNCT07290985 | Gastroesophageal Adenocarcinoma | Phase 2 | RECRUITING | 242 | Dec 1, 2028 | ||||||
| Tislelizumab Monoclonal antibodyMarketedNCT07733180 | Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | RECRUITING | 30 | Feb 28, 2028 | ||||||
| Tislelizumab Monoclonal antibodyMarketedNCT07554521 | Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | RECRUITING | 30 | Dec 31, 2031 | ||||||
| Sonrotoclax Small moleculeNCT06073821 | CLL | Phase 3 | ACTIVE NOT_RECRUITING | 652 | Dec 1, 2032 | ||||||
| Tacabrutideg Small moleculeNCT06846671 | CLL | Phase 3 | RECRUITING | 250 | Feb 14, 2030 | ||||||
| Tacabrutideg Small moleculeNCT06970743 | Chronic Lymphocytic Leukemia | Phase 3 | ACTIVE NOT_RECRUITING | 653 | Nov 30, 2029 | ||||||
| Sonrotoclax Small moleculeNCT06637501 | Chronic Lymphocytic Leukemia | Phase 3 | ACTIVE NOT_RECRUITING | 1,482 | Sep 1, 2029 | ||||||
| Sonrotoclax Small moleculeMarketedNCT05471843 | Mantle Cell Lymphoma | Phase 3 | ACTIVE NOT_RECRUITING | 425 | Jan 31, 2027 | ||||||
| Sonrotoclax Small moleculeNCT05479994 | Leukemia | Phase 2 | ACTIVE NOT_RECRUITING | 100 | Aug 25, 2027 | ||||||
| Sonrotoclax Small moleculeNCT05952037 | Waldenstrom Macroglobulinemia | Phase 2 | ACTIVE NOT_RECRUITING | 114 | Aug 1, 2028 | ||||||
| Tacabrutideg Small moleculeNCT07005713 | Chronic Spontaneous Urticaria | Phase 1 | RECRUITING | 58 | Nov 30, 2026 | ||||||
| Sonrotoclax Small moleculeMarketedNCT04883957 | Mature B-cell Malignancies | Phase 1 | ACTIVE NOT_RECRUITING | 501 | Jun 1, 2026 | ||||||
| Sonrotoclax Small moleculeNCT06497062 | Acute Myeloid Leukemia | Phase 1 | ACTIVE NOT_RECRUITING | 307 | Jun 30, 2028 | ||||||
| Sonrotoclax Small moleculeNCT07770698 | Relapsed Acute Myeloid Leukemia | Phase 1 | NOT YET_RECRUITING | 30 | Sep 1, 2031 | ||||||
| Sonrotoclax Small moleculeNCT04973605 | Relapsed/Refractory Multiple Myeloma | Phase 1 | RECRUITING | 246 | Nov 1, 2026 | ||||||
| Tacabrutideg Small moleculeNCT06634589 | B-cell Malignancy | Phase 1 | RECRUITING | 915 | Dec 2, 2029 | ||||||
| BG-C9074 Small moleculeNCT07811271 | Epithelial Ovarian Cancer | Phase 3 | NOT YET_RECRUITING | 600 | Mar 31, 2033 |
Clinical Trial Results
Readouts, endpoints and source filings for every ONC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ZIIHERA | HER2+ gastroesophageal adenocarcinoma | Phase 3 | 2026-08-31 | statistically significant overall survival benefitRead More | BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lee Chan HenryOfficer (SVP, General Counsel) | Sell | -1,115 | $375.00 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ONC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 12.6 % (-16 %) | 2.51 B | 8.80 M | 0.03% ( 2.51 K) |
ONC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ONC ranks across every disease it competes in
Competitive Position is a premium feature
See how ONC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialONC News
ONCBeOne Medicines anuncia acordo voluntário com o governo dos EUA para expandir o acesso a medicamentos inovadores contra o câncer
BeOne Medicines has announced a voluntary agreement with the U.S. government aimed at expanding access to innovative cancer treatments for American patients. This agreement not only enhances patient access but also strengthens BeOne's manufacturing capabilities in the U.S. and supports large-scale drug provision.
Read more →ONCBeOne Medicines anuncia un acuerdo voluntario con el Gobierno de EE. UU. para ampliar el acceso a medicamentos innovadores contra el cáncer
BeOne Medicines has announced a voluntary agreement with the U.S. government aimed at increasing patient access to innovative cancer treatments. This agreement will bolster the company's production capabilities within the United States, allowing for enhanced large-scale manufacturing of its drugs. The initiative reflects BeOne's commitment to improving cancer care for American patients.
Read more →ONCRiassunto: BeOne Medicines annuncia un accordo volontario con l'Amministrazione degli Stati Uniti per ampliare l'accesso a farmaci oncologici innovativi
BeOne Medicines has announced a voluntary agreement with the U.S. Administration to enhance access to innovative oncology drugs for American patients. This agreement also aims to strengthen the company's production presence in the U.S. and expand the necessary capabilities for large-scale drug supply.
Read more →ONCBeOne Medicines gibt freiwillige Vereinbarung mit der US-Regierung bekannt, um den Zugang zu innovativen Krebsmedikamenten zu erweitern
BeOne Medicines has announced a voluntary agreement with the US government to enhance access to innovative cancer medications for American patients. This initiative also aims to strengthen the company's production presence in the USA and expand its capabilities for large-scale drug provision. The agreement reflects a commitment to improving healthcare access.
Read more →ONCSamenvatting: BeOne Medicines kondigt vrijwillige overeenkomst met Amerikaanse overheid aan om toegang tot innovatieve kankermedicijnen te vergroten
BeOne Medicines has announced a voluntary agreement with the U.S. government aimed at enhancing access to innovative cancer treatments for American patients. This initiative not only focuses on improving patient access but also aims to strengthen U.S. manufacturing capabilities and expand the large-scale delivery of medications.
Read more →ONCBeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
BeOne Medicines Ltd. will present at the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026. The company will participate in a fireside chat scheduled for 11:30 a.m. EDT. Investors can access a live webcast of the event through the company's website, with an archived version also available.
Read more →ONCBeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
BeOne Medicines has entered a voluntary agreement with the U.S. Government to enhance access to innovative cancer treatments for American patients. This initiative also aims to bolster BeOne's manufacturing capabilities in the U.S., ensuring the delivery of medicines at scale. The agreement reflects the company's dedication to patient access and ongoing investment in research.
Read more →ONCBeOne Medicines gibt neue Überlebensdaten aus Phase-3-Studien bekannt, die den Nutzen von ZIIHERA-haltigen Therapien bei HER2-positivem gastroösophagealem Krebs in der Erstlinienbehandlung untermauern
BeOne Medicines announced positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 study. The study evaluates ZIIHERA (Zanidatamab) combined with chemotherapy, with or without TEVIMBRA (Tislelizumab), for treating HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. These findings support the drug's potential as a first-line treatment.
Read more →ONCSamenvatting: BeOne Medicines kondigt nieuwe overlevingsgegevens uit Fase 3-studie aan die het voordeel bevestigen van behandelregimes met ZIIHERA bij eerstelijnsbehandeling van HER2-positieve gastro-oesofageale kanker
BeOne Medicines announced positive interim results from the Phase 3 HERIZON-GEA-01 study. The study evaluated ZIIHERA in combination with chemotherapy, with or without TEVIMBRA, for first-line treatment of HER2-positive gastro-esophageal cancer. These results confirm the treatment's benefits for patients with advanced or metastatic disease.
Read more →ONCRiassunto: BeOne Medicines annuncia i nuovi dati sulla sopravvivenza di Fase 3 a supporto del beneficio dei regimi a base di ZIIHERA nel trattamento di prima linea dei tumori gastroesofagei (GEA) HER2-positivi
BeOne Medicines announced positive preliminary results from the Phase 3 HERIZON-GEA-01 study. The trial evaluates ZIIHERA (zanidatamab) combined with chemotherapy, with or without TEVIMBRA (tislelizumab), for first-line treatment of locally advanced HER2-positive gastroesophageal adenocarcinoma. These results support the potential benefits of ZIIHERA in this patient population.
Read more →ONCBeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines has reported positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 trial. The trial evaluates ZIIHERA in combination with chemotherapy for treating HER2+ gastroesophageal adenocarcinoma. The findings reinforce the benefit of ZIIHERA-containing regimens as a first-line treatment option.
Read more →ONCRiassunto: BeOne Medicines annuncia l'approvazione da parte dell'FDA statunitense del regime a base di TEVIMBRA per il trattamento di prima linea dell'adenocarcinoma gastroesofageo (GEA) HER2-positivo
BeOne Medicines has received FDA approval for TEVIMBRA, a treatment for HER2-positive gastroesophageal adenocarcinoma. This approval allows TEVIMBRA to be used in combination with ZIIHERA and chemotherapy for adult patients. The approval marks a significant advancement in the treatment options available for this patient population.
Read more →ONCSamenvatting: BeOne Medicines kondigt goedkeuring door Amerikaanse FDA aan voor een op TEVIMBRA gebaseerd behandelregime bij eerstelijnsbehandeling van HER2+ GEA
BeOne Medicines has received FDA approval for a supplemental biologics license application for TEVIMBRA (tislelizumab) in combination with ZIIHERA (zanidatamab) and chemotherapy. This approval is specifically for the first-line treatment of adult patients with unresectable HER2+ gastric or gastroesophageal junction adenocarcinoma. This marks a significant advancement in treatment options for this patient population.
Read more →ONCBeOne Medicines gibt die Zulassung durch die US-amerikanische FDA für eine auf TEVIMBRA basierende Therapie zur Erstlinienbehandlung von HER2-positiver GEA bekannt
BeOne Medicines has announced that the FDA has approved a supplemental biologics license application for TEVIMBRA (Tislelizumab) in combination with ZIIHERA (Zanidatamab) and chemotherapy. This therapy is intended for first-line treatment of adult patients with inoperable, locally advanced, or metastatic HER2-positive gastric cancer. This approval represents a significant advancement in treatment options for this patient population.
Read more →ONCBeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
BeOne Medicines has received FDA approval for its TEVIMBRA-based regimen, which includes ZIIHERA and chemotherapy, aimed at treating adult patients with unresectable locally advanced or metastatic HER2-positive gastric and gastroesophageal junction cancer. This approval marks a significant advancement in the treatment options available for this patient population.
Read more →ONCSamenvatting: BeOne Medicines, BeOne Care Foundation en The Max Foundation verlengen samenwerking om toegang tot BRUKINSA® voor de behandeling van chronische lymfatische leukemie in lage- en middeninkomenslanden te vergroten
BeOne Medicines, along with the BeOne Care Foundation and The Max Foundation, has announced the extension of their collaboration until 2028. This partnership aims to enhance access to BRUKINSA® (zanubrutinib) for treating chronic lymphocytic leukemia in low- and middle-income countries. The initiative reflects a commitment to improving healthcare accessibility.
Read more →ONCRiassunto: BeOne Medicines, BeOne Care Foundation e The Max Foundation rinnovano la collaborazione per ampliare l'accesso a BRUKINSA® per il trattamento della leucemia linfatica cronica nei Paesi a reddito medio-basso
BeOne Medicines, in partnership with the BeOne Care Foundation and The Max Foundation, has renewed its collaboration until 2028 to enhance access to BRUKINSA® for chronic lymphocytic leukemia treatment. This initiative targets low-to-middle-income countries, aiming to improve healthcare outcomes in these regions.
Read more →ONCBeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
BeOne Medicines, in collaboration with the BeOne Care Foundation and The Max Foundation, has renewed their partnership until 2028. This initiative aims to improve access to BRUKINSA® for patients with chronic lymphocytic leukemia in low- and middle-income countries. The partnership emphasizes the importance of addressing healthcare inequalities in cancer treatment.
Read more →ONCSamenvatting: BeOne Medicines en Revolution Medicines kondigen samenwerking aan voor klinische ontwikkeling en regionale commercialisering
BeOne Medicines and Revolution Medicines have announced a multi-faceted collaboration aimed at advancing clinical development and regional commercialization of targeted therapies for RAS-dependent cancers. This partnership combines the strengths of both companies to enhance their capabilities in oncology. The collaboration is expected to accelerate the development of innovative treatment options.
Read more →ONCBeOne Medicines und Revolution Medicines kündigen Zusammenarbeit bei klinischer Entwicklung und regionaler Vermarktung an
BeOne Medicines and Revolution Medicines have announced a multi-faceted collaboration aimed at advancing clinical development and regional marketing of targeted therapies for RAS-dependent cancers. This partnership leverages the strengths of both companies in oncology, potentially benefiting patients with these specific cancer types.
Read more →About BeOne Medicines Ltd.
HeadquartersC/O BEONE MEDICINES I GMBH, BASEL, 4051
BIOPHARMAWATCH ELITE PLUS
Trade the next ONC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime